Basal Forebrain Modulation of Olfactory Coding In Vivo.

Sensory perception is one of the most fundamental brain functions, allowing individuals to properly interact and adapt to a constantly changing environment. This process requires the integration of bottom-up and topdown neuronal activity, which is centrally mediated by the basal forebrain, a brain region that has been linked to a series of cognitive processes such as attention and alertness. Here, we review the latest research using optogenetic approaches in rodents and in vivo electrophysiological recordings that are shedding light on the role of this region, in regulating olfactory processing and decisionmaking. Moreover, we summarize evidence highlighting the anatomical and physiological differences in the basal forebrain of individuals with autism spectrum disorder, which could underpin the sensory perception abnormalities they exhibit, and propose this research line as a potential opportunity to understand the neurobiological basis of this disorder.

La percepción sensorial es una de las funciones cerebrales más fundamentales, permitiendo a los individuos interactuar de manera apropiada con el entorno y adaptarse a un ambiente en constante cambio. Este proceso requiere la integración de la actividad neuronal ascendente y descendente, que es mediada por el cerebro basal (BF), una región cerebral que ha sido asociada a una serie de procesos cognitivos, como estados de atención y alerta.En este trabajo revisamos las últimas investigaciones que han utilizado optogenética y registros electrofisiológicos in vivo que han iluminado el rol del BF en el procesamiento olfatorio y la toma de decisiones. Además, resumimos la literatura que destaca las alteraciones fisiológicas y anatómicas del BF de individuos con trastornos del espectro autista, que podrían subyacer las anormalidades en la percepción que presentan, y proponemos esta línea de investigación como una posible oportunidad para entender las bases neurobiológicas de este trastorno.

Biomarker and Companion Diagnostics-A Review of Medicinal Products Approved by the European Medicines Agency.

Background: An increasing number of medicines authorised in Europe recommend or require biomarker-based patient selection. For some of these the use of a companion diagnostic (CDx), a subset of in vitro diagnostics (IVDs), to identify patient populations eligible for a specific medicinal product may be required. The information and recommendations of use of a medicinal product for which a CDx is required is particularly important to healthcare professionals for correct patient identification. Methods: We reviewed the existing information in SmPCs and European Public Assessment Reports (EPARs) of EU medicinal products approved via the centralised procedure at EMA where reference was made to biomarker testing, including by CDx, for patient selection. Results: The results show that varying levels of detail are provided for the biomarker and the diagnostic test, including variability in where the information was presented. The overall results demonstrate transparent but sometimes heterogeneous reporting of CDx in the SmPC and EPAR. Conclusions: With the introduction of the new Regulation (EU) 2017/746 on in vitro diagnostic medical devices, medicines regulatory authorities' will be required to be consulted during the review of CDx conformity assessment and so, there is opportunity for more consistent and transparent information on CDx to be provided in the SmPC and EPAR.